PDX-Derived Organoids: How This Mini-Tumor Transforming Cancer Research?

Imagine if we could grow tiny versions of a patient’s tumor in the lab, acting almost exactly like the real thing. PDXOs, the lab-growing 3D models, are not just cool science, they are changing how we discover and test disease treatment. Download our PDX Model poster presented at AACR 2025 So, what exactly are PDXOs? […]

Boston Innovation Meets ADME Precision

Smarter ADME Screening. Flexible Bundle. Greater Confidence. Flexible Screening Panels That Evolve With Your Pipeline. We get it – early discovery is fast-moving and complex. That’s why our bundled in vitro ADME panels are designed for your workflow, whether you choose one, two, or a full suite. Speed, Clarity, and Tailored Flexibility. and we are […]

Medicilon—Developing PDX-Derived Organoid Models for Efficacy Evaluation of Anticancer Therapies (Download)

PDX-derived organoids combine the genetic fidelity of patient tumors with the scalability and speed of in vitro platforms—delivering a powerful model for evaluating therapeutic response. These models enable:🔷 More accurate efficacy prediction🔷 Reduced translational gaps🔷 Faster iteration for lead optimization This approach strengthens the bridge between preclinical data and clinical outcomes—empowering oncology researchers to make […]

Medicilon Appoints Dr. Lilly Xu as Chief Technology Officer

Medicilon, a leading preclinical contract research organization (CRO), has named Dr. Lilly Xu as its new Chief Technology Officer (CTO). With over 30 years of experience in preclinical drug development, Dr. Xu will lead Medicilon’s technological innovation and global expansion, strengthening its capabilities to deliver cutting-edge R&D solutions. Dr. Lilly Xu Chief Technology Officer of Medicilon […]